Immunogenic cell death in cold tumors: transforming immune-excluded tumors into immunotherapy-sensitive lesions
Frontiers in Pharmacology · 07.05.2026 · 17
DOI: 10.3389/fphar.2026.1732407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.05.2026. Verfasst von Haibo Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunogenic cell death (ICD) is a distinct mode of regulated cell death capable of activating adaptive immune responses against tumor antigens, offering great promise for cancer immunotherapy. However, immune-excluded or “cold” tumors, characterized by poor immune infiltration and limited responsiveness to conventional immunotherapies, remain a major clinical challenge. ICD induction has emerged as a compelling strategy to convert these immunologically inert tumors into immunotherapy-sensitive, immune-active (“hot”) lesions by promoting dendritic cell activation, antigen presentation, and cytotoxic T-cell infiltration. This mini-review article highlights the potential of ICD-based therapeutic interventions, such as chemotherapy, radiotherapy, phototherapy, and nanoparticle-mediated delivery systems, to reprogram the immunosuppressive tumor microenvironment. By effectively converting cold tumors into immunologically responsive entities, ICD-centric approaches may significantly enhance the clinical efficacy of existing immunotherapies, highlighting the need for further translational research and personalized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Zitieren
APA
Zhao, H., & Dai, S. (2026). Immunogenic cell death in cold tumors: transforming immune-excluded tumors into immunotherapy-sensitive lesions. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1732407
Vancouver
Zhao H, Dai S. Immunogenic cell death in cold tumors: transforming immune-excluded tumors into immunotherapy-sensitive lesions. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1732407
BibTeX
@article{Zhao2026,
author = {Zhao, Haibo and Dai, Shiyou},
title = {Immunogenic cell death in cold tumors: transforming immune-excluded tumors into immunotherapy-sensitive lesions},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1732407}
}
EUVIMED